MedTrace Logo

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

NCT04155749 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-11

No results posted yet for this study

Summary

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

Conditions

  • Relapsed and Refractory Multiple Myeloma

Interventions

DRUG

anitocabtagene-autoleucel

Chimeric Antigen Receptor T cells

Sponsors & Collaborators

  • Arcellx, Inc.

    collaborator INDUSTRY

  • Kite, A Gilead Company

    lead INDUSTRY

Principal Investigators

  • Arcellx, Inc. · Arcellx, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-23
Primary Completion
2024-10-03
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04155749 on ClinicalTrials.gov